These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26195059)

  • 1. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
    Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
    Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
    Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
    Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 5. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
    Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
    Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
    BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
    Boulicault D; Duddy M
    Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449
    [No Abstract]   [Full Text] [Related]  

  • 17. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED
    Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
    J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
    Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
    Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.